{"prompt": "['Cochlear', 'CIP Number: CBAS5751', 'Term', 'Description', 'OFS', 'Osia Fitting Software', 'OTE', 'Off-The-Ear (sound processor)', 'PI', 'Principal Investigator', 'PTA', 'Pure Tone Average', 'RF', 'Radio Frequency', 'SADE', 'Serious Adverse Device Effect', 'SAE', 'Serious Adverse Event', 'SAP', 'Statistical Analysis Plan', 'SD', 'Standard Deviation', 'SNHL', 'Sensorineural hearing loss', 'SNR', 'Signal To Noise Ratio', 'SP', 'Sound Processor', 'SPL', 'Sound Pressure Level', 'SSD', 'Single-sided Sensorineural Deafness', 'SSQ', 'Speech, Spatial and Qualities of Hearing Scale', 'UADE', 'Unanticipated Adverse Device Effect', 'USADE', 'Unanticipated Serious Adverse Device Effect', 'Template 1278855 Version 1.0', '12 of 75']['Cochlear\u00ae', 'CIP Number: CBAS5751', '2', 'CLINICAL INVESTIGATION SYNOPSIS', 'Investigation', 'A prospective, multicentre, open clinical investigation evaluating clinical', 'title', 'performance, safety and patient reported outcomes with an Active', 'Osseointegrated Steady-State Implant System (OSI) in adult subjects with', 'conductive hearing loss, mixed hearing loss or single-sided sensorineural', 'deafness', 'Short title', 'Clinical performance, safety and PROs of an Active Osseointegrated', 'Steady-State Implant System (OSI).', 'Investigation number', 'CBAS5751', 'Name of', 'The Osia 2 System includes:', 'Investigational', 'device(s)', 'The OSI200 Implant surgically placed under the skin behind the ear.', 'The BI300 Implant osseointegrated in the bone.', 'The Osia 2 Sound Processor (SP) placed externally connecting to OSI200', 'Implant by magnetic retention.', 'Intended use of', 'The Cochlear Osia 2 System is indicated for patients with conductive', 'Investigational', 'hearing loss (CHL), mixed hearing loss (MHL) and single-sided', 'device(s)', 'sensorineural deafness (SSD). Patients should have sufficient bone quality', 'and quantity to support successful implant placement. The Osia 2 System is', 'indicated for patients with up to 55 dB SNHL.', 'The regulatory status is pre-market.', 'Name and description', 'Not applicable', 'of comparator', 'device/product(s)', 'Expected start date', 'Aug 2019', '(first subject consented)', 'Expected enrolment', '4 6 months', 'period', 'Expected duration per', '6 months', 'subject', 'Expected total', '12 - 15 months', 'duration of the clinical', 'investigation', 'Number of subjects', '30 subjects', 'planned', 'Number of', '3 sites', 'investigational sites', 'planned', 'Inclusion criteria', '1. Subject with CHL or MHL in the ear to be implanted. Bone conduction', 'thresholds with pure tone average (PTA4; mean of 0.5, 1, 2 and 4 kHz) of', '55 dB SNHL.', 'OR', 'Template 1278855 Version 1.0', '13 of 75']['Cochlear', 'CIP Number: CBAS5751', 'Subject with SSD who is a candidate for Baha surgery. Air conduction', 'thresholds with a pure tone average PTA4 (mean of 0.5, 1, 2 and 3 kHz) of', '20 dB SNHL in the good ear OR subject who is indicated for an AC CROS', '(Air Conduction-Contralateral Routing of Signal) but-for some reason-', 'cannot or will not use an AC CROS.', '2. Adult subjects (18 years or older).', '3. Previous experience from amplified sound through properly fitted', 'amplification (for example but not limited to Hearing aid, CROS device,', 'Bone conduction hearing device on softband).', '4. Candidate is a fluent speaker in the language used to assess speech', 'perception performance.', '5. Willing and able to provide written informed consent.', 'Exclusion criteria', '1. Uncontrolled diabetes as judged by the investigator.', '2. Condition that could jeopardise osseointegration and/or wound healing', '(e.g. osteoporosis, psoriasis, long-term systemic use of corticosteroids) or', 'condition that may have an impact on the outcome of the investigation as', 'judged by the investigator.', '3. Insufficient bone quality and quantity to support successful implant', 'placement.', '4. Previous surgery and/or implantation with any bone conduction/active', 'device on the side to be implanted, which may jeopardise the implantation', 'and use of the Osia 2 system, as judged by the investigator.', '5. Use of ototoxic drugs that could be harmful to the hearing, as judged by', 'the investigator.', '6. Unable to follow investigational procedures, e.g. to complete quality of life', 'scales, or unwilling to comply with the requirements of the clinical', 'investigation as determined by the investigator.', '7. Condition with a likely negative progression and/or with expected relapses', 'jeopardising general wellbeing and health-related quality of life as judged by', 'the investigator.', '8. Subject that has received radiotherapy in the area of implantation or is', 'planned for such radiotherapy during the study period.', '9. Investigator site personnel directly affiliated with this study and/or their', 'immediate families; immediate family is defined as a spouse, parent, child,', 'or sibling.', '10. Cochlear employees or employees of Contract Research Organisations', 'or contractors engaged by Cochlear for the purposes of this investigation', '11. Currently participating, or participated within the last 30 days, in another', 'interventional clinical investigation involving an investigational drug or', 'device.', 'Template 1278855 Version 1.0', '14 of 75']\n\n###\n\n", "completion": "END"}